

Benjamin Garmezy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8517330/publications.pdf>

Version: 2024-02-01

10
papers

162
citations

1477746

6
h-index

1588620

8
g-index

10
all docs

10
docs citations

10
times ranked

196
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100267.	1.5	28
2	A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. <i>Blood Reviews</i> , 2021, 45, 100691.	2.8	17
3	Combination antiangiogenic tyrosine kinase inhibition and anti- PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	1.3	15
4	All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. <i>Journal of Bone Oncology</i> , 2021, 31, 100399.	1.0	12
5	Correlation of pathogenic <i>POLE</i> mutations with clinical benefit to immune checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3008-3008.	0.8	11
6	Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17090-e17090.	0.8	0
7	Identifying functional loss of <i>ATM</i> gene in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3629-3629.	0.8	1
8	Characterization of Mortality in Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S353.	0.2	1
9	The oncology prognosis and informed consent: Presentation of a new model to best inform patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 146-146.	0.8	0
10	Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis . <i>Journal of Pediatrics</i> , 2014, 165, 990-996.	0.9	77